Azafaros is a startup based in the Netherlands, most recent round Series B, 4 tracked investors.
Azafaros is a startup based in the Netherlands. Its most recent tracked round is Series B. Brouky records 4 investors associated with the company.
Azafaros develops therapeutic agents for the treatment of rare metabolic disorders, specifically lysosomal storage disorders, through oral administration of aza-sugar compounds. Their lead program, nizubaglustat, targets neurological symptoms in conditions like GM1/GM2 gangliosidoses and Niemann-Pick type C disease.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.